625 related articles for article (PubMed ID: 32974975)
21. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond.
Pertwee RG
Addict Biol; 2008 Jun; 13(2):147-59. PubMed ID: 18482430
[TBL] [Abstract][Full Text] [Related]
22. Ligands for cannabinoid receptors, promising anticancer agents.
Nikan M; Nabavi SM; Manayi A
Life Sci; 2016 Feb; 146():124-30. PubMed ID: 26764235
[TBL] [Abstract][Full Text] [Related]
23. The neurobiology and evolution of cannabinoid signalling.
Elphick MR; Egertová M
Philos Trans R Soc Lond B Biol Sci; 2001 Mar; 356(1407):381-408. PubMed ID: 11316486
[TBL] [Abstract][Full Text] [Related]
24. Modern approaches to the development of synthetic cannabinoid receptor probes.
Saldaña-Shumaker SL; Grenning AJ; Cunningham CW
Pharmacol Biochem Behav; 2021 Apr; 203():173119. PubMed ID: 33508249
[TBL] [Abstract][Full Text] [Related]
25. [Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?].
Saito VM; Wotjak CT; Moreira FA
Braz J Psychiatry; 2010 May; 32 Suppl 1():S7-14. PubMed ID: 20512266
[TBL] [Abstract][Full Text] [Related]
26. Endocannabinoid system in sexual motivational processes: Is it a novel therapeutic horizon?
Androvicova R; Horacek J; Stark T; Drago F; Micale V
Pharmacol Res; 2017 Jan; 115():200-208. PubMed ID: 27884725
[TBL] [Abstract][Full Text] [Related]
27. The complications of promiscuity: endocannabinoid action and metabolism.
Alexander SP; Kendall DA
Br J Pharmacol; 2007 Nov; 152(5):602-23. PubMed ID: 17876303
[TBL] [Abstract][Full Text] [Related]
28. An endocannabinoid hypothesis of drug reward and drug addiction.
Onaivi ES
Ann N Y Acad Sci; 2008 Oct; 1139():412-21. PubMed ID: 18991888
[TBL] [Abstract][Full Text] [Related]
29. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease.
Han QW; Yuan YH; Chen NH
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109745. PubMed ID: 31442553
[TBL] [Abstract][Full Text] [Related]
30. The endocannabinoid-CB receptor system: Importance for development and in pediatric disease.
Fride E
Neuro Endocrinol Lett; 2004; 25(1-2):24-30. PubMed ID: 15159678
[TBL] [Abstract][Full Text] [Related]
31. Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling.
Hiley CR; Ford WR
Biol Rev Camb Philos Soc; 2004 Feb; 79(1):187-205. PubMed ID: 15005177
[TBL] [Abstract][Full Text] [Related]
32. The emerging role of the endocannabinoid system in the sleep-wake cycle modulation.
Murillo-Rodriguez E; Poot-Ake A; Arias-Carrion O; Pacheco-Pantoja E; Fuente-Ortegon Ade L; Arankowsky-Sandoval G
Cent Nerv Syst Agents Med Chem; 2011 Sep; 11(3):189-96. PubMed ID: 21919868
[TBL] [Abstract][Full Text] [Related]
33. Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders.
Manera C; Arena C; Chicca A
Recent Pat CNS Drug Discov; 2016; 10(2):142-156. PubMed ID: 27193072
[TBL] [Abstract][Full Text] [Related]
34. The molecular basis for neuroimmune receptor signaling.
Rogers TJ
J Neuroimmune Pharmacol; 2012 Dec; 7(4):722-4. PubMed ID: 22935971
[TBL] [Abstract][Full Text] [Related]
35. Endocannabinoids and Their Pharmacological Actions.
Pertwee RG
Handb Exp Pharmacol; 2015; 231():1-37. PubMed ID: 26408156
[TBL] [Abstract][Full Text] [Related]
36. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
37. The endocannabinoid system in Huntington's disease.
Pazos MR; Sagredo O; Fernández-Ruiz J
Curr Pharm Des; 2008; 14(23):2317-25. PubMed ID: 18781982
[TBL] [Abstract][Full Text] [Related]
38. The therapeutic potential of novel cannabinoid receptors.
Kreitzer FR; Stella N
Pharmacol Ther; 2009 May; 122(2):83-96. PubMed ID: 19248809
[TBL] [Abstract][Full Text] [Related]
39. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
[TBL] [Abstract][Full Text] [Related]
40. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
